Holen Sie sich die Stockscreener-App
31.00
1.71%
-0.54
Handel nachbörslich:
31.00
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$31.54
Offen:
$31.48
24-Stunden-Volumen:
1.03M
Relative Volume:
0.62
Marktkapitalisierung:
$5.11B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
15.90
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
+2.48%
1M Leistung:
-1.27%
6M Leistung:
-0.61%
1J Leistung:
+28.15%
1-Tages-Spanne:
$30.92
$31.48
1-Wochen-Bereich:
$29.70
$31.70
52-Wochen-Spanne:
$22.90
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Vergleichen Sie ALKS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
31.00 | 4.99B | 1.51B | 333.35M | 315.22M | 1.95 |
|
HLN
Haleon Plc Adr
|
11.12 | 50.98B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.61 | 74.41B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.93 | 4.03M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.99 | 46.23B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.25 | 20.10B | 16.54B | -1.64B | 749.00M | -1.45 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Substance Abuse Treatment Market Set to Witness Digital and Personalized Care Expansion | Indivior, Alkermes - openPR.com
Controlled Release Drug Delivery Market Is Booming So Rapidly - openPR.com
Nanotechnology Drug Delivery Market Set to Witness Significant - openPR.com
Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences - The Malaysian Reserve
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | ALKS Stock News - GuruFocus
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - marketscreener.com
Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation? - simplywall.st
Where are the Opportunities in (ALKS) - news.stocktradersdaily.com
Cetera Investment Advisers Increases Stock Position in Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 20 - GuruFocus
Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 2025 | ALKS Stock News - GuruFocus
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 - PR Newswire
Global Healthcare & Medical Tourism News - Medical Tourism Magazine
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Needham Initiates Coverage on Alkermes (ALKS) with Buy Rating | - GuruFocus
Needham Initiates Alkermes Public at Buy With $45 Price Target - marketscreener.com
Needham's Positive Outlook on Alkermes (ALKS) with Promising Sal - GuruFocus
Needham's Positive Outlook on Alkermes (ALKS) with Promising Sales Projections | ALKS Stock News - GuruFocus
Quantinno Capital Management LP Acquires New Position in Alkermes plc (NASDAQ:ALKS) - Defense World
Controlled Release Drug Delivery Market Generated - openPR.com
Bank of America Corp DE Trims Stake in Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes Shareholders Approve Amendments at Annual Meeting - TipRanks
(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Alkermes price target raised to $35 from $34 at BofA - MSN
Captrust Financial Advisors Raises Stock Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World
Nanotechnology Drug Delivery Market Generated Opportunities, - openPR.com
Stifel maintains Alkermes stock Buy rating, $42 target By Investing.com - Investing.com Nigeria
Drug Addiction Treatment Market Projected To Witness Massive - openPR.com
Drug Abuse Treatment Market Grows Amid Rising Substance Abuse - openPR.com
Cantor Fitzgerald maintains $43 target on Alkermes stock By Investing.com - Investing.com Nigeria
Controlled Release Drug Delivery Market is in trends - openPR.com
Alkermes plc Earnings Call Highlights Growth and R&D Progress - MSN
When the Price of (ALKS) Talks, People Listen - news.stocktradersdaily.com
Alkermes plc (ALKS): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Alkermes plc (NASDAQ:ALKS) Q1 2025 Earnings Call Transcript - Insider Monkey
Alkermes has near-term catalyst with narcolepsy data, says H.C. Wainwright - TipRanks
BlackRock, Inc. Reduces Stake in Alkermes PLC: A Detailed Analysis - GuruFocus
RBC Capital Raises Price Target for Alkermes (ALKS) to $40 | ALKS Stock News - GuruFocus
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates - Nasdaq
Alkermes (ALKS) Reaffirms 2025 Financial Outlook and Awaits Key Trial Results | ALKS Stock News - GuruFocus
Alkermes (ALKS) Price Target Raised to $41 by Baird Analyst | AL - GuruFocus
Alkermes (ALKS) Price Target Raised to $41 by Baird Analyst | ALKS Stock News - GuruFocus
Baird Increases Price Target for Alkermes (ALKS) on Promising Ou - GuruFocus
Baird Increases Price Target for Alkermes (ALKS) on Promising Outlook | ALKS Stock News - GuruFocus
RBC Raises Price Target on Alkermes to $40 From $39, Keeps Sector Perform Rating - marketscreener.com
Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ... - Yahoo
Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Pro - GuruFocus
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alkermes Plc-Aktie (ALKS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Parisi Samuel Joseph | VP, Finance (Interim PAO) |
Feb 25 '25 |
Sale |
35.26 |
3,743 |
131,978 |
7,717 |
| Parisi Samuel Joseph | VP, Finance (Interim PAO) |
Feb 20 '25 |
Sale |
35.69 |
1,327 |
47,361 |
7,717 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 13 '25 |
Option Exercise |
30.12 |
144,419 |
4,350,097 |
202,294 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 12 '25 |
Option Exercise |
19.64 |
199,196 |
3,912,871 |
262,796 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 12 '25 |
Sale |
32.78 |
204,921 |
6,718,278 |
57,875 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 13 '25 |
Sale |
35.53 |
144,419 |
5,130,698 |
57,875 |
1.51%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):